Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCTB35 + GemOx vs R-GemOx in R/R DLBCL
NCT07570823Phase 3Recruiting
- Sponsor
- Sinocelltech Group Limited
- Start
- Jun 2026
- Primary completion
- Nov 2027
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of SCTB35 in diffuse large B-cell lymphoma (DLBCL), sponsored by Sinocelltech Group Limited. Started Jun 2026; status: recruiting.
02
Drugs
SCTB35
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07570823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07570823.